Summary: Pregabalin is the first drug to receive approved ... twice daily or 50 mg three times daily and may be increased to 600 mg daily based on individual response and tolerability.
and pregabalin (300 mg, 450 mg and 600 mg daily). Compared with placebo, these three agents showed “modest” risk differences ranging from 0.09 to 0.14, while the numbers needed to treat ranged ...
Each participant was treated with 150–600 mg pregabalin daily. After 8 weeks, 74% of patients showed a notable improvement in symptoms, with a third of these patients becoming completely pain free.
TCAs are equally effective compared to non-AD drugs gabapentin (1200–3600 mg/day) and pregabalin (150–600 mg/day) SSRI: not recommended Painful Diabetic Neuropathy (PDN) 25–29 ADs recommended:?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results